Salix Pharmaceuticals Ltd.  (SLXP) Trade Now »     Rate SLXP  -  Discuss SLXP  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

SLXP: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

FDA, Clinical Trial Calendar Updates: WYE, SVNT, AMRN, ISIS, SLXP, SOMX SLXP

73%

+100.77% in 187 days <> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo... Continue reading »

Favorable risk / reward profile SLXP

4 %

+155.37% in 680 days Favorable risk / reward profile for comparative analysis, other stocks with favorable risk / reward profiles, and potential short-term reversals, visit:   http://f1.grp.yahoofs.com/v1/8EF3R4tbNvpbI1SUgN2s5cv3kn0S2YU_...   http://f1.grp.yahoofs.com/v1/8EF3R8IApDlbI1SUEwj9ACPoO-N506V3...   http://finance.groups.yahoo.com/group/vectortrades/ Continue reading »

From the Blogosphere

Unusual 11 Mid-Day Movers 9/14: ZOOM, SLXP, BRNC, HDY Higher; AMIE, ALXA, ALTI, CDE Lower

Zoom Technologies, Inc. (NASDAQ: ZOOM) <font>84.2% HIGHER;</font> surging higher today after announcing the results of its recently approved acquisition, Gold Lion. The newly acquired company reported Q2 revenue increased 354% to $53.1 million; net income in the quarter grew to to $1.7 million, versus a net loss of $0.1 million last year; Gold Lion management's FY09 net revenue guidance in the range of $145-$155 million, versus $81 million in 2008; Gold Lion management's FY09 net income guidance in the range of $5.9-$6.1 million, versus $2.8 million in 2008.Salix Pharmaceuticals, Ltd. (NASD... Continue reading »

Morning Movers 9/14: SLXP, S, KERX, ARIA, HDY Higher; ALXA, EE, SAH, CWTR Lower

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) <font>54.4% HIGHER;</font> announced the successful outcome of two Phase 3, randomized, double-blind, placebo-controlled, multicenter trials, TARGET 1 and TARGET 2, designed to evaluate the efficacy and safety of rifaximin 550 mg TID in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS). Click here for the full report.Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) <font>30% LOWER;</font> announced preliminary results from its 366 patient Phase 2b clinical trial of AZ-104 in patients with migraine headache. Both AZ-104... Continue reading »

Challenges for Sell-Rated Salix SLXP

-182.21% in 524 days We expect 2008 to be an extremely challenging year for the company with a significant decline in both revenues and earnings. Continue reading »

MFI Shortbusters for May 2008

N/A

This month's MFI Shortbusters portfolio is as follows: Blyth (BTH) Cymer (CYMI) Heelys (HLYS) * LCA Vision (LCAV) LoopNet (LOOP) NutriSystem (NTRI) * Salix Pharmaceuticals (SLXP) Sierra Wireless (SWIR) Systemax (SYX) Travelzoo (TZOO) Volcom (VLCM) * appeared in last month's MFI Shortbusters screen As a reminder, the Shortbuster criteria is as follows: Shares Short as a Percentage of Float >= 20 Shares Short Current Month <= Shares Short Prior Month The first Shortbusters portfolio will have aged to the one-year holding period next month, so look for performance updates to begin at that point. Continue reading »

Pressures Keep Salix a Sell SLXP

-16.48% in 27 days (closed on 06/03/08) We expect 2008 to be an extremely challenging year for the company with a significant decline in both revenues and earnings. Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.